3-[6-(1-isopropyl-1H-pyrazol-4-yl)-pyrimidin-4-yloxy]-phenylamine | 943314-58-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 3-[6-(1-isopropyl-1H-pyrazol-4-yl)-pyrimidin-4-yloxy]-phenylamine
• 英文别名: 3-[6-(1-Propan-2-ylpyrazol-4-yl)pyrimidin-4-yl]oxyaniline
• CAS: 943314-58-7
• 化学式: C₁₆H₁₇N₅O
• 分子量: 295.344
• InChiKey: OQVJCECMKJSXTC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  78.8
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• NOVEL SUBSTITUTED PYRIMIDINYLOXY UREAS USEFUL AS INHIBITORS OF PROTEIN KINASES
  申请人：Lang Hengyuan

  公开号：US20070155764A1

  公开（公告）日：2007-07-05

  The present invention relates to compounds and methods useful as inhibitors of protein kinases, including B-Raf and several receptor tyrosine and cytoplasmic tyrosine kinases. The present invention is directed to new substituted pyrimidinyloxy urea compounds of Formulas II, III and IV and compositions and their application as pharmaceuticals for the treatment of disease. Methods of modulating of protein kinase activity in a human or animal subject are also provided for the treatment diseases such as cancers.

  本发明涉及化合物和方法，用作蛋白激酶的抑制剂，包括B-Raf以及几种受体酪氨酸激酶和细胞质酪氨酸激酶。本发明涉及新的取代嘧啶氧基脲化合物II、III和IV的配方及其作为药物治疗疾病的应用。还提供了在人类或动物主体中调节蛋白激酶活性的方法，用于治疗癌症等疾病。
• Therapeutic acridone and acridine compounds
  申请人：Neidle Stephen

  公开号：US20060111389A1

  公开（公告）日：2006-05-25

  The present invention pertains to acridone and acridine compounds of formula (I), wherein either: (a) K is ═O, L is —H, alpha is a single bond, beta is a double bond, gamma is a single bond (acridones): or, (b) K is a 9-substituent. L is absent, alpha is a double bond, beta is a single bond, gamma is a double bond and wherein: J 1 is a 2- or 3-substituent; J 2 is a 6- or 7-substituent; J 1 and J 2 are each independently a group of the formula —NHCO(CH 2 ) n NR 1 R 2 , wherein: n is an integer from 1 to 5; and, R 1 and R 2 are independently hydrogen, C 1-7 alkyl, C 3-20 heterocyclyl, or C 5-20 aryl, or R 1 and R 2 , taken together with the nitrogen atom to which they are attached, form a heterocyclic ring having from 3 to 8 ring atoms; and wherein, when K is a 9-substituent, K is a group of the formula —N(R N )Q, wherein: R N is an amino substituent and is hydrogen. C 1-7 alkyl, C 3-20 heterocyclyl, or C 5-20 aryl; and, Q is C 1-7 alkyl, C 3-20 heterocyclyl, or C 5-20 aryl, and is optionally substituted; and pharmaceutically acceptable salts, esters, amides, solvates, hydrates and protected forms thereof. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo to inhibit telomerase, to regulate cell proliferation, and in the treatment of proliferative conditions, such as cancer.

  本发明涉及式（I）的喹啉和吖啶化合物，其中：（a）K为═O，L为—H，α为单键，β为双键，γ为单键（吖啶酮）；或者（b）K为9-取代基，L不存在，α为双键，β为单键，γ为双键，其中：J1为2-或3-取代基；J2为6-或7-取代基；J1和J2各自独立地为式—NHCO(CH2)nNR1R2的基团，其中：n为1至5的整数；R1和R2各自独立地为氢，C1-7烷基，C3-20杂环基或C5-20芳基，或R1和R2连同它们所连接的氮原子形成具有3至8个环原子的杂环环；当K为9-取代基时，K为式—N(RN)Q的基团，其中：RN为氨基取代基，且为氢、C1-7烷基、C3-20杂环基或C5-20芳基；Q为C1-7烷基、C3-20杂环基或C5-20芳基，并且可以取代；以及其药学上可接受的盐、酯、酰胺、溶剂合物、水合物和保护形式。本发明还涉及包含这种化合物的制药组合物，以及这种化合物和组合物的使用，在体内外抑制端粒酶，调节细胞增殖，并用于治疗增殖性疾病，如癌症。
• THERAPEUTIC ACRIDONE AND ACRIDINE COMPOUNDS
  申请人：Cancer Research Technology Limited

  公开号：EP1363888A2

  公开（公告）日：2003-11-26
• US7160896B2
  申请人：——

  公开号：US7160896B2

  公开（公告）日：2007-01-09
• US7300930B2
  申请人：——

  公开号：US7300930B2

  公开（公告）日：2007-11-27